Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05488132
Other study ID # XYFY2022-KL119-01
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 1, 2022
Est. completion date March 31, 2025

Study information

Verified date March 2022
Source Xuzhou Medical University
Contact Kailin Xu, M.D., Ph.D.
Phone 15162166166
Email lihmd@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of anti-Siglec-6 CAR-T cells in the treatment of relapsed and refractory acute myeloid leukemia.


Description:

Sialic acid-binding immunoglobulin-like lectins (Siglec) are a class of classical immunoglobulin-like lectins. Studies have shown that Siglec-6 is commonly expressed in AML but not detected on normal hematopoietic stem and progenitor cells (HSC/P). In vitro experiments revealed that anti-Siglec-6 CAR-T cell treatment did not affect the viability or lineage differentiation in colony-forming assays. These data suggest that anti-SigLlec-6 is an ideal target with great potential for treating acute myeloid leukemia.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 31, 2025
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: 1. All subjects must sign and date the Informed Consent before initiating any study specific procedures or activities; 2. At the age of 18-70 years old; 3. Diagnosed as relapse/refractory (r/r) de novo or secondary acute myeloid leukemia (AML); 4. The patient has recovered from the toxicity of previous treatment; 5. ECOG score = 2 and expected survival period is not less than 3 months; 6. Adequate organ function defined as:AST =3×ULN; ALT =3×ULN; Total bilirubin =1.5×ULN; Serum creatinine =1.5×ULN, or CCR=60 mL/min; Hemoglobin =60g/L ; Indoor oxygen saturation =92%; LVEF=45%; 7. Pregnancy testing: females of childbearing potential must have a negative serum or urine pregnancy test; 8. From the use of study drug to 2 years after treatment, males and female of childbearing potential must agree to use an effective method of contraception. Exclusion Criteria: 1. Diagnosis of acute promyelocytic leukemia; 2. History or presence of a CNS disorder; 3. HBsAg is positive; HCV ?HIV or Syphilis antibody are positive, CMV DNA in peripheral blood is more than=500 copies /mL; 4. History of severe hypersensitivity reaction; 5. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, New York Heart Association Class II or greater congestive heart failure, atrial fibrillation, or other clinically significant cardiac disease within 12 months before enrollment; 6. History of organ transplant surgery; 7. Required systemic application of immunosuppressive or other drugs; 8. Auto-SCT within the 3 months before enrollment; 9. Active autoimmune or inflammatory diseases of the nervous system (e.g., Guillain-Barre syndrome (GBS), amyotrophic lateral sclerosis (ALS)) and clinically active cerebrovascular diseases (e.g., cerebral edema, posterior reversible encephalopathy syndrome (PRES)); 10. Requirement for urgent therapy due to ongoing or impending oncologic emergency (eg, leukostasis or tumor lysis syndrome (TLS)) ; 11. Presence or suspicion of a fungal, bacterial, viral, or other infection that is uncontrolled or requiring antimicrobials for management; 12. Live vaccine received within the = 4 weeks before enrollment; 13. Persons with serious mental illness; 14. History of major surgical operations four weeks before enrollment; 15. History of alcoholism or substance abuse; 16. Was identified by the investigators as unsuitable to participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
anti-siglec-6 CAR-T cell therapy
Enrolled patients will receive prespecified dose of autologous CAR-T cells.

Locations

Country Name City State
China Kailin Xu Xuzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Xuzhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity(DLT) Adverse events assessed according to NCI-CTCAE v5.0 criteria Baseline up to 28 days after T cell infusion
Secondary MRD negative overall response rate (MRD- ORR) Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment 3 months
Secondary Overall response rate (ORR) Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24 Month 6, 12, 18 and 24
Secondary Event-free survival (EFS) Assessment of EFS at Month 6, 12, 18 and 24 Month 6, 12, 18 and 24
Secondary Overall survival (OS) Assessment of OS at Month 6, 12, 18 and 24 Time Frame: Month 6, 12, 18 and 24
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02204085 - A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Recruiting NCT06125652 - Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML) Phase 1/Phase 2
Recruiting NCT05105152 - PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML Phase 1
Recruiting NCT05597306 - Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT04898894 - Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia Phase 1
Recruiting NCT05546580 - Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) Phase 1
Recruiting NCT03957915 - Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse/Refractory Acute Leukemia Early Phase 1
Recruiting NCT05317403 - Venetoclax to Augment Epigenetic Modification and Chemotherapy Phase 1
Recruiting NCT04867928 - Venetoclax and Azacitidine for the Management of Molecular Relapse/Progression in Adult NPM1-mutated Acute Myeloid Leukemia Phase 2
Completed NCT04402541 - Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Not yet recruiting NCT04716452 - Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05211570 - AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2
Terminated NCT03690154 - A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML Phase 1
Not yet recruiting NCT06459024 - Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Not yet recruiting NCT05854966 - CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT05735184 - A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients With AML Phase 1
Recruiting NCT05124288 - Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
Recruiting NCT05506332 - Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia Phase 1
Recruiting NCT05949125 - Dose-escalating Trial With Allo-RevCAR01-T Cells in Combination With CD123 Target Module (R-TM123) for Participants With Selected Hematologic Malignancies Positive for CD123 Phase 1
Recruiting NCT06128044 - CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia Phase 1